Rafael Fonseca, MD

Rafael Fonseca, MD, shares an overview of the treatment armamentarium for patients with relapsed/refractory multiple myeloma.

Practical advice on strategies to improve care for patients with transplant-ineligible multiple myeloma regarding induction and maintenance therapy, and aiming for deep and durable responses.

Expert perspectives on updated data from the MAIA trial in newly diagnosed transplant-ineligible multiple myeloma and how this can be applied to clinical practice.

Rafael Fonseca, MD, provides details on a patient case of transplant-ineligible multiple myeloma and reviews the selection of frontline triplet versus doublet therapy.

Rafael Fonseca, MD, reviews efficacy and safety data from the phase 3 MAIA trial and discusses their implications for clinical practice.

Rafael Fonseca, MD, discusses the role of monoclonal antibodies in the first-line setting in patients with newly diagnosed multiple myeloma.

Rafael Fonseca, MD, reviews first-line therapy options and considerations for treatment selection for patients with newly diagnosed multiple myeloma.

Rafael Fonseca, MD, discusses the challenges of treating patients with newly diagnosed multiple myeloma.

Rafael Fonseca, MD, reviews the case overview of a 77-year-old woman with multiple myeloma.

Rafael Fonseca, MD, discusses the case of a 77-year-old woman with multiple myeloma, treatment approach for patients with newly diagnosed multiple myeloma, and the trials providing insight into the treatment of this disease.

During a virtual Targeted Oncology Case-Based Roundtable event, Rafael Fonseca, MD, lead a discussion on how MRD status can guide treatment of multiple myeloma